Basilea Pharmaceutica (BSLN) Stock Statistics & Valuation Metrics

Basilea Pharmaceutica has a market cap or net worth of CHF613.65M. The enterprise value is CHF609.47M.

Basilea Pharmaceutica has 13,313,530 shares outstanding. The number of shares has decreased by -2.65% in one year.

Basilea Pharmaceutica’s return on equity (ROE) is 0.96 and return on invested capital (ROIC) is 36.76%.

The current PE Ratio of Basilea Pharmaceutica is 6.44. Basilea Pharmaceutica’s PEG ratio is <0.01.

In the last 12 months, Basilea Pharmaceutica had revenue of 208.54M and earned 77.59M in profits. Earnings per share was 6.42.

In the last 12 months, operating cash flow was 74.36M and capital expenditures -1.71M, giving a free cash flow of 72.65M billion.

Basilea Pharmaceutica pays an annual dividend of CHF5, resulting in a dividend yield of ―

Basilea Pharmaceutica upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.

Basilea Pharmaceutica as a current ratio of 4.85, with Debt / Equity ratio of 137.87%

In the past 12 months, Basilea Pharmaceutica has paid -17.33M in taxes.

Basilea Pharmaceutica EV to EBITDA ratio is 7.78, with an EV/FCF ratio of 6.76.

Basilea Pharmaceutica has CHF120.71M in cash and marketable securities with CHF111.67M in debt, giving a net cash position of -CHF9.04M billion.

Gross margin is 60.57%, with operating margin of 29.34%, and net profit margin of 37.21%.

The average price target for Basilea Pharmaceutica is CHF83.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy